TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19178175

Group type: EXPERIMENTAL
Intervention: PK Superpulse transurethral resection of the prostate (TURP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional transurethral resection of the prostate (TURP)
Number of subjects: 70
Study: 17534541

Group type: EXPERIMENTAL
Intervention: Sitz bath (twice daily) along with analgesics and fiber supplement
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (analgesics and fiber supplement only)
Number of subjects: 46
Study: 15144991

Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional ultrafiltration
Number of subjects: 23

Group type: COMPARATOR
Intervention: Ultrafiltration
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ultrafiltration and PD
Number of subjects: 23
Study: 11714853

Group type: EXPERIMENTAL
Intervention: High trans stick margarine (SM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Soybean oil (SO)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low trans squeeze margarine (SQM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Medium trans tub margarine (TM)
Number of subjects: 14
Study: 9917711

Group type: EXPERIMENTAL
Intervention: Immediate weightbearing as tolerated
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nonweightbearing for 2 weeks
Number of subjects: 49
Study: 8306409

Group type: EXPERIMENTAL
Intervention: OK-432 i.p. for 7 days, intradermal injection for 1 year at 2-week intervals
Number of subjects: 109

Group type: COMPARATOR
Intervention: Mitomycin C (MMC) and UFT (tegafur and uracil in a molar ratio of 1:4) for 1 year
Number of subjects: 109
Study: 3394332

Group type: EXPERIMENTAL
Intervention: Deverol drgs. (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Osiren drgs. (100 mg)
Number of subjects: 0
Study: 29888570

Group type: EXPERIMENTAL
Intervention: Acupuncture plus intra-articular injection of sodium hyaluronate (2 mL once a week for 5 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Simple medication (intra-articular injection of sodium hyaluronate 2 mL once a week for 5 weeks)
Number of subjects: 150
Study: 29083275

Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1204

Group type: COMPARATOR
Intervention: OADs and insulin
Number of subjects: 1204
Study: 25433502

Group type: EXPERIMENTAL
Intervention: Ground almonds
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sliced almonds
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Whole almonds
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Ground hazelnuts
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sliced hazelnuts
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Whole hazelnuts
Number of subjects: 74
Study: 23244028

Group type: EXPERIMENTAL
Intervention: Telephone-delivered cognitive-behavioral therapy (T-CBT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Telephone-delivered pain education (T-EDU)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both T-CBT and T-EDU
Number of subjects: 98
Study: 21564387

Group type: EXPERIMENTAL
Intervention: Phenobarbital monotherapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: No anti-epileptic therapy
Number of subjects: 128
Study: 18089849

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (5 g/m(2) over 24 hours)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Intermediate-dose methotrexate (1 g/m(2) over 36 hours)
Number of subjects: 269
Study: 16687201

Group type: EXPERIMENTAL
Intervention: Single IUI performed 36 h after HCG administration combined with timed intercourse
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: IUI alone performed 36 h after HCG administration
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Double IUI performed 12 and 36 h after HCG administration
Number of subjects: 94
Study: 14556831

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 2051

Group type: COMPARATOR
Intervention: Clinical touch method
Number of subjects: 2051
Study: 15635799

Group type: COMPARATOR
Intervention: IFN alpha 2 b (5MU sqm/daily)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: IFN alpha 2 b (5MU sqm/daily) plus monthly courses of low-dose AraC
Number of subjects: 43
Study: 8844876

Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxapram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1626759

Group type: EXPERIMENTAL
Intervention: Grass pollen extract (10,000 BU)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Histamine challenge
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 10
Study: 6206105

Group type: EXPERIMENTAL
Intervention: Active treatment with a mean cumulative dose of cat allergen, 10.9 units
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 17
Study: 29101777

Group type: EXPERIMENTAL
Intervention: Real PENS therapy with etoricoxib, 3 times per week for 8 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham PENS therapy with etoricoxib, 3 times per week for 8 weeks
Number of subjects: 72
Study: 30341123

Group type: EXPERIMENTAL
Intervention: eHealth tools including satellite communications
Number of subjects: 0
Study: 27449712

Group type: EXPERIMENTAL
Intervention: Vincristine, etoposide, and carboplatin (VEC)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Carboplatin and etoposide, alternating with cyclophosphamide, idarubicin, and vincristine
Number of subjects: 54
Study: 25170535

Group type: EXPERIMENTAL
Intervention: Retropubic midurethral sling (RP)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Transobturator midurethral sling (TO)
Number of subjects: 54
Study: 22577748

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study: 19524262

Group type: EXPERIMENTAL
Intervention: 40 mg Parecoxib
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0.9% normal saline solution
Number of subjects: 32
Study: 18030450

Group type: EXPERIMENTAL
Intervention: Ayahuasca (1 mg DMT kg(‐1) body weight)
Number of subjects: 22

Group type: COMPARATOR
Intervention: d-amphetamine (20 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15223094

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - 3 sessions
Number of subjects: 71

Group type: COMPARATOR
Intervention: Educational videos and home visit - 2 videos and 1 home visit
Number of subjects: 71
Study: 11403190

Group type: EXPERIMENTAL
Intervention: Circumcised white men
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Uncircumcised Hispanic men
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Uncircumcised white men
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Uncircumcised black men
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Clinician gender (both women)
Number of subjects: 532
Study: 9586596

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8024729

Group type: EXPERIMENTAL
Intervention: Diet therapy for 15 months
Number of subjects: 71
Study: 2509380

Group type: EXPERIMENTAL
Intervention: TDN 20 (transdermal nitroglycerin patches, 20 mg over 24 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chronic TDN treatment
Number of subjects: 10
Study: 911371

Group type: EXPERIMENTAL
Intervention: Chemotherapy group (clofibrate 1 g twice daily and nicotinic acid 1 g three times daily)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control group (moderate diet advice only)
Number of subjects: 558
Study: 29377141

Group type: EXPERIMENTAL
Intervention: Gender-neutral vaccination with AS04-adjuvanted HPV16/18 vaccine (Arm A)
Number of subjects: 11675

Group type: EXPERIMENTAL
Intervention: HPV vaccination of girls and hepatitis B-virus (HBV) vaccination of boys (Arm B)
Number of subjects: 11675

Group type: COMPARATOR
Intervention: Gender-neutral HBV vaccination (Arm C)
Number of subjects: 11675
Study: 27780487

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 0
Study: 24689255

Group type: EXPERIMENTAL
Intervention: Physical simulation of an underground bolting machine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Virtual simulation of a generic device
Number of subjects: 48
Study: 21923735

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Caloric restriction plus exercise (CR+EX)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 63
Study: 20042557

Group type: EXPERIMENTAL
Intervention: Light sedation (BIS >or=80)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Deep sedation (BIS approximately 50)
Number of subjects: 114
Study: 18852481

Group type: EXPERIMENTAL
Intervention: Sequential Combined Treatment (SCT)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Treatment as Usual (TU)
Number of subjects: 209
Study: 15730352

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 mg per week
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo three times daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydergine 1 mg three times daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 25/100 mg three times daily
Number of subjects: 60
Study: 14522476

Group type: EXPERIMENTAL
Intervention: Abciximab (ABC)
Number of subjects: 1780

Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENOX)
Number of subjects: 1780

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 1780
Study: 10979909

Group type: EXPERIMENTAL
Intervention: II CPS-TT conjugate vaccine (dose range, 3.6-57 microg of CPS component)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Uncoupled II CPS vaccine
Number of subjects: 75
Study: 8684103

Group type: EXPERIMENTAL
Intervention: Serum 1,5-anhydroglucitol (1,5AG) monitoring in group A (continuous treatment)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Serum 1,5-anhydroglucitol (1,5AG) monitoring in group B (intermittent treatment)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fasting plasma glucose (FPG) monitoring
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Correlation of 1,5AG with FPG and mean daily plasma glucose
Number of subjects: 56
Study: 1611648

Group type: EXPERIMENTAL
Intervention: Loracarbef 400 mg twice daily for 10 to 14 days
Number of subjects: 134

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 500/125 mg three times daily for 10 to 14 days
Number of subjects: 134
Study: 6705901

Group type: EXPERIMENTAL
Intervention: Low dose antidepressants (75 mg/day)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: High dose antidepressants (150 mg/day)
Number of subjects: 370
Study: 30158392

Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 60
Study: 29653644

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting, durable polymer-coated Resolute Onyx stent
Number of subjects: 2470

Group type: COMPARATOR
Intervention: Sirolimus-eluting, bioresorbable polymer-coated Orsiro stent
Number of subjects: 2470
Study: 26243733

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) delivered by promotores
Number of subjects: 698

Group type: COMPARATOR
Intervention: Assessed condition (control)
Number of subjects: 698
Study: 25321641

Group type: EXPERIMENTAL
Intervention: CSRP services (multicomponent, classroom‐based mental health intervention)
Number of subjects: 0
Study: 22571507

Group type: EXPERIMENTAL
Intervention: Caspofungin (Arm C)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (Arm B)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No antifungal treatment (Arm A)
Number of subjects: 110
Study: 20195154

Group type: EXPERIMENTAL
Intervention: Heart‐Age message
Number of subjects: 413

Group type: COMPARATOR
Intervention: Percentage risk message
Number of subjects: 413
Study: 17591019

Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of patients to HCs at week 96
Number of subjects: 24
Study: 15764869

Group type: EXPERIMENTAL
Intervention: Sabeluzole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caregiver assistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caregiver type
Number of subjects: 0
Study: 11837553

Group type: EXPERIMENTAL
Intervention: Everolimus 2 mg orally under fasting conditions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Everolimus 2 mg orally after a high-fat meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Everolimus 2.5 mg/day orally in patients with renal transplants under fasting conditions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Everolimus 2.5 mg/day orally in patients with renal transplants after a high-fat meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Everolimus trough levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Peak-trough fluctuation of everolimus
Number of subjects: 30
Study: 10091411

Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (no rhGM-CSF)
Number of subjects: 46
Study: 8672324

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (serum concentrations > or = 200 kiu ml‐1)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 3661477

Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no taurine supplementation)
Number of subjects: 21
Study: 29321047

Group type: EXPERIMENTAL
Intervention: MAG‐EPA supplementation (6 capsules of 625 mg of fish oil daily, containing 500 mg of EPA)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: MAG‐EPA supplementation
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo (high oleic acid sunflower oil)
Number of subjects: 130
Study: 26526300

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TNA) applied during and after intense pulsed light (IPL) treatment.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vehicle (control) applied during and after intense pulsed light (IPL) treatment.
Number of subjects: 15
Study: 25391867

Group type: EXPERIMENTAL
Intervention: Iodixanol 270, low tube output, iterative reconstruction (SAFIRE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Iopromide 370, conventional tube output, filtered back projection (FBP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (Iodixanol 270 and Iopromide 370)
Number of subjects: 120
Study: 23573081

Group type: EXPERIMENTAL
Intervention: MyCPAP website intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC, control)
Number of subjects: 0
Study: 20723998

Group type: EXPERIMENTAL
Intervention: Maternal depression severity
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Poor maternal sleep
Number of subjects: 69
Study: 18761570

Group type: EXPERIMENTAL
Intervention: Variolink II
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chemiace II
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Super-Bond C&B
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Panavia F
Number of subjects: 120
Study: 20499339

Group type: EXPERIMENTAL
Intervention: SQSTM1 mutation carriers
Number of subjects: 737
Study: 16369731

Group type: EXPERIMENTAL
Intervention: bLF tablets at a dosage of 200 mg b.i.d. for a period of 12 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo tablets without bLF
Number of subjects: 59
Study: 11561799

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg daily for 3 days
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 9396979

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg bid
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg bid
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 240 mg bid
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study: 7954759

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 3812344

Group type: EXPERIMENTAL
Intervention: Excessive alcohol consumption (case men)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control men
Number of subjects: 26
Study: 11800042

Group type: EXPERIMENTAL
Intervention: rhBDNF (25 microg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rhBDNF (100 microg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31718402

Group type: EXPERIMENTAL
Intervention: Geisinger Maternal Fetal Medicine obesity protocol (MOP)
Number of subjects: 97
Study: 30876777

Group type: EXPERIMENTAL
Intervention: Intradermal mesotherapy with tenoxicam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous dexketoprofen (control)
Number of subjects: 0
Study: 29207249

Group type: EXPERIMENTAL
Intervention: Supporting Physical Activity in the Childcare Environment (SPACE) intervention
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 234
Study: 27424229

Group type: EXPERIMENTAL
Intervention: Overfeeding with Renutryl® Booster (600 kcal, 30g protein, 72g carbohydrate, 21g fat) for 2 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (BMI 20-25 kg/m2)
Number of subjects: 30
Study: 24964886

Group type: EXPERIMENTAL
Intervention: Imageless navigation
Number of subjects: 125

Group type: COMPARATOR
Intervention: Fluoroscopy
Number of subjects: 125
Study: 22140199

Group type: COMPARATOR
Intervention: Computer-based compensatory therapy (CT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Restorative computerized training (RT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard occupational therapy (OT)
Number of subjects: 45
Study: 20206437

Group type: EXPERIMENTAL
Intervention: U-type method of TVT SECUR
Number of subjects: 285

Group type: COMPARATOR
Intervention: H-type method of TVT SECUR
Number of subjects: 285
Study: 17272964

Group type: EXPERIMENTAL
Intervention: Donepezil (5-10 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 21
Study: 16376775

Group type: EXPERIMENTAL
Intervention: Percutaneous mitral commissurotomy (PMC)
Number of subjects: 120
Study: 12063921

Group type: EXPERIMENTAL
Intervention: New immediate early management prosthesis with individually adjustable air chambers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomechanical cadaver study with the prostheses
Number of subjects: 0
Study: 9468082

Group type: EXPERIMENTAL
Intervention: 80 degrees tilt protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: edrophonium provocation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: isoproterenol challenge
Number of subjects: 0
Study: 7892894

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 to 80 mg daily from 12 weeks' gestation until delivery)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 24
Study: 2711266

Group type: EXPERIMENTAL
Intervention: Aspiration of amoebic liver abscess (ALA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-aspiration
Number of subjects: 80
Study: 1111463

Group type: EXPERIMENTAL
Intervention: intermittent courses of carmustine with prednisone
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: continued courses of melphalan with prednisone
Number of subjects: 508

Group type: COMPARATOR
Intervention: no chemotherapy
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: continued melphalan-prednisone chemotherapy
Number of subjects: 508
Study: 31242506

Group type: EXPERIMENTAL
Intervention: Brief mindfulness intervention (BMG)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Gratitude journal intervention (GJG)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 234
Study: 28084175

Group type: EXPERIMENTAL
Intervention: Antidiabetic drugs (including metformin)
Number of subjects: 78615

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 78615

Group type: EXPERIMENTAL
Intervention: Sulphonylureas
Number of subjects: 78615

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones or insulin
Number of subjects: 78615

Group type: COMPARATOR
Intervention: Non-users of antidiabetic drugs
Number of subjects: 78615
Study: 25356749

Group type: EXPERIMENTAL
Intervention: Live presentation mode; emotional demeanor
Number of subjects: 81

Group type: COMPARATOR
Intervention: Video presentation mode; emotional demeanor
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Live presentation mode; neutral demeanor
Number of subjects: 81

Group type: COMPARATOR
Intervention: Video presentation mode; neutral demeanor
Number of subjects: 81
Study: 23153149

Group type: EXPERIMENTAL
Intervention: Mass media messages (thematic mediators: selection, pleasure, and negotiation)
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Mass media exposure
Number of subjects: 1139
Study: 22164968

Group type: EXPERIMENTAL
Intervention: Coated azithromycin powder for suspension (Tridosil 200 mg/5 ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Uncoated azithromycin powder for suspension (200 mg/5 ml)
Number of subjects: 24
Study: 19896041

Group type: EXPERIMENTAL
Intervention: Platelet-enriched gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-gel group
Number of subjects: 100
Study: 16953150

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 32
Study: 21067346

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg once daily)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Lisinopril (20 mg once daily)
Number of subjects: 68
Study: 10394450

Group type: EXPERIMENTAL
Intervention: Intraoral saccharose administration
Number of subjects: 37

Group type: COMPARATOR
Intervention: Water administration
Number of subjects: 37